Middle East AI In Oncology Market Size, Share, Growth, Report 2025 to 2034
The Middle East AI in oncology market size was valued at USD 111.65 million in 2024 and is projected to hit around USD 812.89 million by 2034, growing at a CAGR of 21.96% during the forecast period 2025 to 2034. The growth of the market is driven by the rising prevalence of cancer, government initiatives to improve healthcare, and advancements in AI technologies.
Key Takeaways
- By component, the hardware segment led the market in 2024.
- By component, the software solutions segment is expected to grow at the fastest rate between 2025 and 2034.
- By cancer type, the breast cancer segment dominated the market in 2024.
- By cancer type, the prostate cancer segment is likely to expand at the fastest CAGR during the projection period.
- By application, the diagnostics segment dominated the market in 2024.
- By application, the research & development segment is expected to expand at the highest CAGR over the forecast period.
- By end-use, the hospitals segment contributed the largest market share in 2024.
- By end-use, the surgical centers & medical institutes segment is expected to experience rapid growth in the coming years.
Market Overview
The Middle East AI in oncology market revolves around the use of artificial intelligence technologies, such as machine learning and deep learning, to enhance cancer detection, diagnostics, treatment planning, and patient management throughout the region. AI improves early diagnosis and treatment precision by accurately analyzing complex clinical and imaging datasets, support clinical decision-making, and streamline oncology workflows, enabling more effective identification of tumors and tailored therapies. The market is experiencing significant growth, driven by rising cancer prevalence, expanding healthcare data infrastructure, increasing investments from governments and private entities, and the evolution of regulatory frameworks across the region.
The growing emphasis on early and accurate cancer diagnosis also bolsters the growth of the market. Early detection significantly improves survival rates, especially for aggressive cancers like lung and pancreatic, making timely diagnosis a top healthcare priority. AI technologies enhance diagnostic precision by analyzing complex imaging and clinical data faster and more accurately than traditional methods. This capability is particularly valuable in areas facing shortages of skilled radiologists and pathologists. As a result, healthcare providers across the region are increasingly adopting AI tools to reduce diagnostic delays and support better-informed treatment decisions, fueling market growth.
Forecasting Cancer Incidence and Mortality in GCC Countries: 2020 to 2040 Percentage Change Analysis
What are the Major Trends in the Middle East AI in Oncology Market?
- Rapid Adoption of AI in Medical Imaging: Hospitals and diagnostic centers across the region are increasingly deploying AI-powered image analysis tools, significantly improving the speed and accuracy of oncology diagnostics. These solutions reduce clinician workload and enhance detection of tumors through automated interpretation of radiology scans.
- Integration with Precision Medicine and Multi‑Modal Data: AI platforms are evolving beyond single data formats to combine imaging, pathology, genomics, and EHRs, enabling more accurate diagnosis and personalized treatment planning. In oncology, this trend supports highly tailored therapeutic strategies based on a comprehensive patient profile.
- Rising Use of Federated Models and AI-Powered Workflows: To overcome data-sharing constraints, stakeholders are gravitating toward federated learning approaches that enable AI model training across institutions without transferring sensitive patient data. Moreover, AI is being embedded directly into clinical workflows, from robotic-assisted surgeries to predictive analytics, marking a move toward smarter, more integrated oncology care systems.
Market Dynamics
Drivers
Increasing Cancer Incidence
The rising incidence of cancer across the Middle East is a key driver fueling the adoption of AI in oncology. As cancer cases increase, particularly breast, lung, and colorectal types, healthcare systems are under pressure to enhance diagnostic speed and accuracy. AI-powered tools offer the ability to detect malignancies earlier through advanced imaging analysis, pattern recognition, and predictive modeling, significantly improving patient outcomes. Governments and hospitals are investing in AI-driven platforms to manage the growing cancer burden more efficiently, reduce diagnostic errors, and support personalized treatment planning. This demand for advanced solutions is accelerating the growth of the market.
- In 2020, GCC countries reported an estimated 42,475 new cancer cases and 19,895 deaths, with breast, colorectal, and thyroid cancers accounting for nearly 40% of all cases. Colorectal and breast cancers were the leading causes of cancer-related deaths. The region’s cancer burden is projected to rise sharply by 116% in Saudi Arabia and up to 270% in Qatar, reaching nearly 104,000 cases by 2040.
Government Initiatives and Investments
In the Middle East, governments are actively spearheading AI adoption in oncology through robust policies, strategic funding, and regulatory frameworks. The UAE’s national AI strategy, anchored in the UAE Centennial 2071 vision, prioritizes healthcare digitization and positions AI at the heart of early disease detection, diagnostics, and personalized treatment through dedicated Centers of Excellence and regulatory bodies. Similarly, Saudi Arabia is making substantial investments under its Vision 2030 agenda, backed by entities like SDAIA and the National Strategy for Data and AI (NSDAI), and is channeling billions into AI infrastructure and R&D to advance oncology solutions. Additionally, countries such as Qatar are implementing clear governance models for AI in healthcare, with frameworks for medical devices and data protection that foster innovation while ensuring patient safety.
Restraints
High Implementation Costs and Data Privacy Concerns
Deploying AI technologies requires substantial investment in infrastructure, skilled personnel, and system integration, which can be a barrier for smaller hospitals and emerging healthcare providers. Additionally, the handling of sensitive patient data, especially genomic and imaging information, raises concerns about security, consent, and compliance with local data protection laws. These challenges are amplified in a region where regulatory frameworks for AI and health data are still evolving. As a result, some institutions remain hesitant to fully adopt AI solutions, slowing market expansion despite the region's growing interest in digital health.
Lack of Skilled Professionals and Regulatory Challenges
The shortage of skilled professionals and complex regulatory environments significantly restrain the growth of the Middle East AI in oncology market. Implementing and managing AI systems requires expertise in data science, oncology, and machine learning—talent that remains limited across many countries in the region. Additionally, regulatory frameworks for AI in healthcare are still maturing, creating uncertainties around approval, integration, and ethical use of AI tools. These gaps hinder innovation, delay deployment, and make it difficult for healthcare institutions to scale AI solutions.
Opportunities
Technological Advancements
Technological advancements are creating significant opportunities in the Middle East AI in oncology market by enhancing the precision, efficiency, and accessibility of cancer care. Innovations in machine learning, deep learning, and cloud-based diagnostics are enabling faster and more accurate detection of cancer through imaging, genomics, and clinical data integration. These tools support personalized treatment plans and early intervention, improving patient outcomes while reducing costs. Additionally, the growing availability of advanced digital infrastructure and 5G connectivity across the region facilitates seamless deployment of AI solutions in both urban and remote healthcare settings. As AI technologies continue to evolve, they open the door for scalable, data-driven oncology care across the Middle East.
Expanding Scope of Applications in Drug Discovery
The expanding use of AI in drug discovery is opening new opportunities in the market. AI algorithms can rapidly analyze complex datasets to identify potential drug targets, predict treatment responses, and shorten the time needed for oncology drug development. This is particularly valuable in a region where cancer rates are rising, and there is a growing demand for innovative, personalized therapies. As research institutions and pharmaceutical companies in the Middle East increasingly adopt AI for oncology R&D, collaboration between academia, healthcare, and tech sectors is intensifying. This trend is positioning the region as an emerging hub for AI-driven oncology drug discovery and development.
Segment Outlook
Component Insights
What Made Hardware the Dominant Segment in the Market in 2024?
In 2024, hardware emerged as the dominant segment in the Middle East AI in oncology market due to the region’s growing investments in digital health infrastructure and diagnostic imaging equipment. Advanced hardware components such as GPUs, AI-enabled imaging devices, and data storage systems are essential for running complex oncology-focused AI algorithms and managing large volumes of patient data. Hospitals and research centers across the Middle East are prioritizing the upgrade of medical hardware to support real-time diagnostics, image processing, and high-speed data analysis. Additionally, the integration of AI capabilities into medical devices like MRI, CT, and PET scanners has further driven hardware demand.
The software solutions segment is expected to experience the fastest growth during the forecast period, owing to the increasing demand for advanced AI-powered platforms that enhance cancer diagnosis, treatment planning, and patient management. Software solutions offer scalability and integration capabilities with existing healthcare infrastructure, making them more accessible for hospitals and clinics across the region. Additionally, continuous advancements in machine learning algorithms and data analytics are driving more accurate and personalized oncology care. The rising adoption of cloud-based solutions and telemedicine also supports rapid software deployment, fueling segmental growth.
Cancer Type Insights
Why Did the Breast Cancer Segment Lead the Market in 2024?
The breast cancer segment led the Middle East AI in oncology market with the largest share in 2024. This is mainly due to its high prevalence and growing focus on early detection and personalized treatment. Breast cancer remains the most commonly diagnosed cancer among women in the region, prompting healthcare systems to adopt AI tools that enhance mammography interpretation, risk prediction, and treatment planning.
AI-driven solutions help radiologists detect tumors with greater accuracy and efficiency, especially in dense breast tissues, reducing diagnostic delays. Governments and private healthcare providers have increasingly invested in AI-powered screening programs and digital imaging infrastructure to improve outcomes. This combination of high disease burden and targeted technological investment positioned breast cancer as the leading segment in the market.
The prostate cancer segment is expected to expand at the fastest CAGR in the upcoming period. This is mainly due to the increasing prevalence of prostate cancer among men in the region. AI technologies are improving early detection and diagnosis through advanced imaging and biomarker analysis, which are critical for effective prostate cancer management. Additionally, AI-driven personalized treatment plans and monitoring are helping to enhance patient outcomes and reduce recurrence rates. Growing awareness, screening programs, and government initiatives focused on men’s health are also accelerating the adoption of AI solutions in prostate cancer care.
- In 2022, the Middle East reported 50,944 new prostate cancer cases, representing 3.47% of the global incidence, with projections showing a significantly higher increase by 2050 compared to Europe and North America. Higher-income countries in the region are expected to see greater rises in incidence, reflecting socioeconomic disparities. These trends underscore the urgent need for targeted awareness, improved screening, better oncology infrastructure, and strengthened cancer registries in the Middle East.
Application Insights
What Made Diagnostics the Dominant Segment in the Market in 2024?
In 2024, the diagnostics segment, particularly pathology and cancer radiology, dominated the Middle East AI in oncology market due to the urgent need for early and accurate cancer detection across the region. AI-powered diagnostic tools significantly enhanced imaging interpretation and pathology workflows, reducing human error and accelerating diagnosis times. The rising cancer burden, coupled with a shortage of specialized oncologists and radiologists in several Middle Eastern countries, further fueled the adoption of AI solutions in diagnostics. Additionally, governments and healthcare providers increasingly invested in digital health infrastructure and AI-driven technologies to improve clinical outcomes and reduce long-term treatment costs.
The research & development (drug design, development process, etc.) segment is expected to grow at the highest CAGR during the projection period due to the increasing emphasis on personalized medicine and targeted cancer therapies. AI accelerates the drug discovery process by analyzing vast datasets to identify potential drug candidates more efficiently and cost-effectively. Additionally, governments and private sectors are investing heavily in oncology research to address the rising cancer burden in the region. The integration of AI in R&D enables faster clinical trials and improved success rates, driving innovation and attracting further investments in this space.
End-Use Insights
How Does Hospitals Contribute the Largest Share of the Middle East AI in Oncology Market?
The hospitals segment dominated the market while holding the largest share in 2024 because hospitals serve as the primary centers for cancer diagnosis, treatment, and patient management. They have greater access to advanced medical infrastructure and a higher volume of cancer patients, making AI integration more impactful and scalable. Additionally, hospitals are increasingly adopting AI technologies to improve workflow efficiency, enhance diagnostic accuracy, and personalize treatment plans, leading to better patient outcomes. Strong government support and investment in hospital digitalization also contributed to this dominance, as hospitals remain the focal point for delivering comprehensive oncology care in the region.
The surgical centers & medical institutes segment is expected to grow at a rapid pace in the coming years due to the increasing adoption of advanced AI-driven surgical technologies and precision medicine. These facilities are focusing more on minimally invasive surgeries and personalized treatment plans, where AI can optimize surgical outcomes and reduce complications. Additionally, medical institutes are expanding their research and training capabilities, leveraging AI to accelerate innovation in cancer treatment. Growing investments in specialized oncology centers and collaborations with technology providers are also driving rapid AI integration in this segment.
Country Level Analysis
In 2024, Saudi Arabia emerged as the dominant force in the Middle East AI in oncology market. The Kingdom's rapid digitalization of healthcare infrastructure, exemplified by initiatives like the Seha Virtual Hospital and the deployment of AI-driven diagnostic platforms, has facilitated the seamless integration of AI technologies into clinical workflows. Furthermore, the establishment of Humain, a national AI company under the Public Investment Fund, underscores Saudi Arabia's commitment to becoming a global leader in AI innovation and infrastructure. These strategic investments and initiatives have positioned Saudi Arabia at the forefront of AI in oncology in the region.
The UAE is poised to experience rapid growth in the coming years. This is mainly due to strong government support, including the UAE Strategy for Artificial Intelligence, which aims to regulate AI and its implementation in healthcare. Additionally, partnerships between the UAE's health services and international institutions, such as the collaboration between the Mohamed bin Zayed University of Artificial Intelligence and Abu Dhabi Health Services Company (SEHA), are fostering innovation and the integration of AI-driven solutions in cancer care.
Middle East AI in Oncology Market - Value Chain Analysis
1. Data Collection and Annotation
This stage involves gathering vast amounts of oncology-related data, such as medical imaging, patient records, and genomic data. Proper annotation and labeling of this data are crucial for training AI algorithms to recognize patterns and assist in diagnosis.
2. AI Algorithm Development
At this stage, developers design and train AI models using machine learning and deep learning techniques tailored for oncology applications like tumor detection, treatment planning, and prognosis prediction. Innovation and accuracy are the focus here.
3. Platform and Software Development
AI solutions are packaged into user-friendly platforms and software that can be integrated into clinical workflows. These platforms offer diagnostic support, treatment recommendations, and data analytics for healthcare professionals.
4. Implementation and Integration
Hospitals and healthcare providers implement AI systems into their oncology departments, ensuring compatibility with existing electronic health records (EHR) and imaging equipment. Training healthcare staff to effectively use AI tools is also vital.
5. Maintenance and Support
Ongoing maintenance, software updates, and technical support are essential to keep AI systems accurate and secure. This stage also involves monitoring AI performance and ensuring compliance with data privacy regulations.
6. Research and Development (R&D)
Continuous R&D helps improve AI capabilities and discover new applications in oncology, such as personalized medicine and early cancer detection. Partnerships between AI firms, healthcare institutions, and academic bodies drive innovation.
Key Players Operating in the Market
1. Lunit Inc.: Lunit's AI-powered imaging solutions, such as Lunit INSIGHT MMG, have been integrated into national cancer screening programs in Qatar and the UAE. These tools assist in early breast cancer detection, aiming to reduce missed diagnoses and improve survival rates.
2. Siemens Healthineers AG: It offers advanced imaging systems and AI-driven analytics platforms that enhance diagnostic accuracy in oncology. Their technologies support clinicians in detecting and characterizing tumors, leading to more precise treatment planning.
3. GE HealthCare: GE HealthCare's AI-enabled imaging and monitoring solutions facilitate real-time analysis of medical images, aiding in the early detection of cancers. Their systems are designed to integrate seamlessly into existing healthcare infrastructures in the Middle East.
4. NVIDIA Corporation: NVIDIA provides high-performance computing platforms essential for training and deploying AI models in oncology. Their GPUs and software frameworks accelerate the development of AI applications for cancer research and treatment.
5. Roche: The company collaborates with AI firms to integrate machine learning into drug discovery and diagnostics. Their efforts focus on personalizing cancer treatments and improving patient outcomes through data-driven insights.
6. Insilico Medicine: Insilico Medicine utilizes AI to design novel small molecules for cancer therapies. Their approach includes the use of generative models to simulate biological data, enhancing the efficiency of drug development processes.
7. Oracle Corporation: Oracle offers cloud-based platforms that support the storage, analysis, and sharing of large-scale oncology datasets. Their solutions enable healthcare providers to implement AI-driven decision-making in cancer care.
8. Intel Corporation: Intel supplies processors and AI accelerators that power computational tasks in oncology research. Their hardware supports the development and deployment of AI applications in cancer diagnostics and treatment planning.
Recent Developments
- In August 2025, Egypt unveiled the Middle East’s first fully Egyptian AI system for early breast cancer detection at Baheya Hospital, Sheikh Zayed. The system analyzes mammograms in seconds, detects abnormal growths, classifies them as benign or malignant, and continuously improves through machine learning.
- In November 2023, Detectiome, a UAE-based AI diagnostics company, launched Revonco, an AI-driven multi-cancer early detection (MCED) test tailored to the Middle East’s genetic profile. Unveiled at the 2023 Expand North Star event in Dubai, Revonco uses generative AI and multiomics to detect multiple cancers at early, asymptomatic stages.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Middle East AI In Oncology Market.
By Component
- Software Solutions
- Hardware
- Services
By Cancer Type
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Brain Tumor
- Other
By Application
- Diagnostics (Pathology, Cancer Radiology)
- Radiation therapy (Radiotherapy)
- Research & Development (Drug design, development process, etc.)
- Chemotherapy
- Immunotherapy
By End-use
- Hospitals
- Surgical Centers & Medical Institutes
- Others (Pharmaceutical companies, Research institutes & training centers)
Request Customization
Get a Sample
Get a Sample
Request Customization